Scarica l'app Stockscreener
826.64
1.69%
-14.20
Dopo l'orario di chiusura:
826.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$840.84
Aprire:
$831.7
Volume 24 ore:
565.87K
Relative Volume:
0.59
Capitalizzazione di mercato:
$85.11B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
20.14
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+2.56%
1M Prestazione:
+22.98%
6M Prestazione:
+6.02%
1 anno Prestazione:
+39.87%
Intervallo 1D:
$826.05
$840.82
Intervallo di 1 settimana:
$792.57
$844.92
Portata 52W:
$541.00
$844.92
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (NASDAQ:REGN) Enters New Healthcare Focus - Kalkine Media
Regeneron stock jumps on FDA approval for ultra-rare bone disorder drug - Ad-hoc-news.de
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class ActionContact SueWallSt - Morningstar
Advanz Looks To Nix Regeneron, Bayer Eye Med Patents - Law360
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment - simplywall.st
Regeneron to challenge Ipsen as FDA clears bone disease drug - BioPharma Dive
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug - Yahoo Finance
REGN Looks 5.6% Undervalued on GF Value™ Amid FDA Approval Boost - GuruFocus
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - lincolnjournal.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - PR Newswire
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Benzinga
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
FDA nod for Regeneron’s Pasatru for ultra-rare genetic disorder FOP - The Pharma Letter
Johnson Financial Group Inc. Buys Shares of 3,250 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
1,311 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Meeder Advisory Services Inc. - MarketBeat
E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DCF Advisers LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News - Yahoo Finance
US FDA approves Regeneron's rare bone disorder drug - CNBC TV18
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses - PR Newswire
Regeneron (REGN) Results Review: Profit Per Share Clears Its Benchmark in the Current Update; Closing Reaction - Vinanet
TLX: Revenue up 22% to $477.3M, net profit $38.3M, boosted by U.S. sales and Regeneron deal - TradingView
US FDA approves Regeneron’s rare bone disorder drug - KELO-AM
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit - Bloomberg Law News
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test - insights.citeline.com
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - Quiver Quantitative
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com - Investing.com Australia
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Oxbow Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meeder Asset Management Inc. Invests $4.46 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds near a 52-week high after a strong quarter. - Ad-hoc-news.de
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - Morningstar
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
23.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):